Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.83 |
| ▸ | CHRM3 | P20309 | 17/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943273 | 0.94 | CHRM2 (0.85) | CHRM2CHRM3ADRB2 | |
| SCHEMBL19154410 | 0.93 | CHRM2 (0.84) | CHRM2CHRM3ADRB2 | |
| SCHEMBL942926 | 0.93 | CHRM2 (0.84) | CHRM2CHRM3ADRB2 | |
| SCHEMBL643392 | 0.92 | CHRM2 (0.78) | CHRM2CHRM3ADRB2SLC2A1 | |
| SCHEMBL643411 | 0.92 | CHRM2 (0.81) | CHRM2CHRM3ADRB2SLC2A1 | |
| SCHEMBL645233 | 0.92 | CHRM2 (0.81) | CHRM2CHRM3ADRB2SLC2A1 | |
| SCHEMBL645936 | 0.92 | CHRM2 (0.81) | CHRM2CHRM3ADRB2SLC2A1 | |
| SCHEMBL643735 | 0.92 | CHRM2 (0.81) | CHRM2CHRM3ADRB2SLC2A1 | |
| SCHEMBL643783 | 0.92 | CHRM2 (0.81) | CHRM2CHRM3ADRB2SLC2A1 | |
| SCHEMBL943530 | 0.92 | CHRM2 (0.83) | CHRM2CHRM3ADRB2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013152-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-09-06 | — | — | US | claimed |
| US-20100197667-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-08-05 | — | — | US | claimed |
| EP-1893577-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2006138218-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060281740-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-12-14 | — | — | US | claimed |
| US-8399488-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120122850-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8119796-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110281851-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-8013152-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100197667-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7728144-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC (US) | 2010-06-01 | — | — | US | disclosed |
| US-20060281740-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197667-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | CHRM2 1/4885CHRM3 2/4885ADRB2 10/4885 |
| US-20110281851-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | CHRM2 1/4885CHRM3 2/4885ADRB2 10/4885 |
| US-20120122850-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | CHRM2 1/4885CHRM3 2/4885ADRB2 10/4885 |
| US-20060281740-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM5 | CHRM2 1/4885CHRM3 2/4885ADRB2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.